Sp97

PROTEOMIC BIOMARKER PROFILING OF AMPULLARY ADENOCARCINOMA (AMPAC) WITHIN THE LANDSCAPE OF PERIAMPULLARY CARCINOMAS TO GUIDE CLINICAL DECISION-MAKING

Date
May 18, 2024

Presenter

Speaker Image for Louisa Bolm
Massachusetts General Hospital

Tracks

Related Products

Thumbnail for LYMPH NODE YIELD IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL AND INCREASED TIME TO RECURRENCE IN NODE-NEGATIVE PANCREATIC DUCTAL ADENOCARCINOMA FOLLOWING NEOADJUVANT THERAPY
LYMPH NODE YIELD IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL AND INCREASED TIME TO RECURRENCE IN NODE-NEGATIVE PANCREATIC DUCTAL ADENOCARCINOMA FOLLOWING NEOADJUVANT THERAPY
Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…
Thumbnail for Residents & Fellows Research Conference
Residents & Fellows Research Conference
RISK FACTORS FOR REGROWTH AFTER NONOPERATIVE MANAGEMENT FOR RECTAL CANCER
Thumbnail for PROTEOMIC BIOMARKER PROFILING OF AMPULLARY ADENOCARCINOMA (AMPAC) WITHIN THE LANDSCAPE OF PERIAMPULLARY CARCINOMAS TO GUIDE CLINICAL DECISION-MAKING
PROTEOMIC BIOMARKER PROFILING OF AMPULLARY ADENOCARCINOMA (AMPAC) WITHIN THE LANDSCAPE OF PERIAMPULLARY CARCINOMAS TO GUIDE CLINICAL DECISION-MAKING
Background: Ampullary adenocarcinoma (AMPAC) are a rare entity of gastrointestinal malignancies arising from the Ampulla of Vater. Together with distal cholangiocarcinoma (DCC) and duodenal adenocarcinoma (DUOAC) AMPAC form the group of periampullary tumors…